Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
Abstract Objectives Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03912-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850273411060727808 |
|---|---|
| author | Hong-ye Peng Chun-li Lu Mo Zhao Xiao-qiang Huang Shu-xia Huang Zi-wen Zhuo Jing Liu Yan-ping Lu Wen-liang Lv |
| author_facet | Hong-ye Peng Chun-li Lu Mo Zhao Xiao-qiang Huang Shu-xia Huang Zi-wen Zhuo Jing Liu Yan-ping Lu Wen-liang Lv |
| author_sort | Hong-ye Peng |
| collection | DOAJ |
| description | Abstract Objectives Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders. Methods The National Health and Nutrition Examination Survey for the 2017–2018 cycle was used to screen the participants. Multivariate-adjusted logistic regression models were applied to explore the difference in relative risk analysis between NAFLD/MAFLD/MASLD/MetALD and metabolic disorders. Results Among the 1,862 eligible individuals, 358(44.84%) had MASLD, 213(11.44%) had MetALD, 841(45.17%) had MAFLD, and 1,125(60.42%) had NAFLD. Positive associations with the risk of hypertension were discovered for MASLD (OR = 2.892, 95%CI = 2.226–3.756), MetALD (OR = 1.802, 95% CI = 1.355–2.398), MAFLD (OR = 3.455, 95%CI = 2.741–4.354) and NAFLD (OR = 1.983, 95%CI = 1.584–2.484). Positive associations with the risk of T2DM were discovered for MASLD (OR = 6.360, 95%CI = 4.440–9.109), MAFLD (OR = 7.026, 95%CI = 4.893–10.090) and NAFLD (OR = 3.372, 95%CI = 2.511–4.528). We discovered similar results for hyperlipidemia. Compared to mild steatosis, moderate to severe steatosis in patients with MASLD (OR = 3.924, 95%CI = 2.399–6.419), MAFLD (OR = 3.814, 95%CI = 2.367–6.144), NAFLD (OR = 4.910, 95%CI = 2.983–8.080) has a higher risk for T2DM. Conclusion The proposed definitions of MASLD and MetALD are valuable and deserve further exploration. Our findings suggest that MAFLD is a more effective indicator for identifying patients at increased risk for metabolic disorders. |
| format | Article |
| id | doaj-art-09eb654f3f8440b0b19c3cf5e609136a |
| institution | OA Journals |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-09eb654f3f8440b0b19c3cf5e609136a2025-08-20T01:51:30ZengBMCBMC Gastroenterology1471-230X2025-05-0125111210.1186/s12876-025-03912-0Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disordersHong-ye Peng0Chun-li Lu1Mo Zhao2Xiao-qiang Huang3Shu-xia Huang4Zi-wen Zhuo5Jing Liu6Yan-ping Lu7Wen-liang Lv8Department of Infection, Guang’anmen Hospital, China Academy of Chinese Medical SciencesGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine (Institute of Traditional Chinese Medicine), Guangdong Pharmaceutical UniversityGraduate School, Beijing University of Chinese MedicineGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine (Institute of Traditional Chinese Medicine), Guangdong Pharmaceutical UniversityDepartment of Infection, Guang’anmen Hospital, China Academy of Chinese Medical SciencesDepartment of Infection, Guang’anmen Hospital, China Academy of Chinese Medical SciencesDepartment of Infection, Guang’anmen Hospital, China Academy of Chinese Medical SciencesDepartment of Hepatology, Shenzhen Baoan Hospital of Traditional Chinese MedicineDepartment of Infection, Guang’anmen Hospital, China Academy of Chinese Medical SciencesAbstract Objectives Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders. Methods The National Health and Nutrition Examination Survey for the 2017–2018 cycle was used to screen the participants. Multivariate-adjusted logistic regression models were applied to explore the difference in relative risk analysis between NAFLD/MAFLD/MASLD/MetALD and metabolic disorders. Results Among the 1,862 eligible individuals, 358(44.84%) had MASLD, 213(11.44%) had MetALD, 841(45.17%) had MAFLD, and 1,125(60.42%) had NAFLD. Positive associations with the risk of hypertension were discovered for MASLD (OR = 2.892, 95%CI = 2.226–3.756), MetALD (OR = 1.802, 95% CI = 1.355–2.398), MAFLD (OR = 3.455, 95%CI = 2.741–4.354) and NAFLD (OR = 1.983, 95%CI = 1.584–2.484). Positive associations with the risk of T2DM were discovered for MASLD (OR = 6.360, 95%CI = 4.440–9.109), MAFLD (OR = 7.026, 95%CI = 4.893–10.090) and NAFLD (OR = 3.372, 95%CI = 2.511–4.528). We discovered similar results for hyperlipidemia. Compared to mild steatosis, moderate to severe steatosis in patients with MASLD (OR = 3.924, 95%CI = 2.399–6.419), MAFLD (OR = 3.814, 95%CI = 2.367–6.144), NAFLD (OR = 4.910, 95%CI = 2.983–8.080) has a higher risk for T2DM. Conclusion The proposed definitions of MASLD and MetALD are valuable and deserve further exploration. Our findings suggest that MAFLD is a more effective indicator for identifying patients at increased risk for metabolic disorders.https://doi.org/10.1186/s12876-025-03912-0MASLDMetALDMetabolic disordersHypertensionT2DMSteatosis severity. |
| spellingShingle | Hong-ye Peng Chun-li Lu Mo Zhao Xiao-qiang Huang Shu-xia Huang Zi-wen Zhuo Jing Liu Yan-ping Lu Wen-liang Lv Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders BMC Gastroenterology MASLD MetALD Metabolic disorders Hypertension T2DM Steatosis severity. |
| title | Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders |
| title_full | Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders |
| title_fullStr | Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders |
| title_full_unstemmed | Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders |
| title_short | Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders |
| title_sort | clinical characteristics of masld metald mafld nafld and the relative risk analysis on metabolic disorders |
| topic | MASLD MetALD Metabolic disorders Hypertension T2DM Steatosis severity. |
| url | https://doi.org/10.1186/s12876-025-03912-0 |
| work_keys_str_mv | AT hongyepeng clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT chunlilu clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT mozhao clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT xiaoqianghuang clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT shuxiahuang clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT ziwenzhuo clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT jingliu clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT yanpinglu clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders AT wenlianglv clinicalcharacteristicsofmasldmetaldmafldnafldandtherelativeriskanalysisonmetabolicdisorders |